1篇
您的检索式：作者名="Hiten RH.Patel"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Are we progressing in prostate cancer management?显示文摘With more than 1.2 million cases worldwide reported in 2018,prostate cancer is one of the most frequently diagnosed malignancies in males[1].Ductal adenocarcinoma(DAC),a rarer subtype,has been reported in its purest form in 0.2%-1.3%of localised prostate cancers,with 0.8%-12.7%co-existing with acinar adenocarcinoma,the most common histological type of prostate cancer[2].Thus,under-recognised forms of prostate cancer can still affect thousands of patients and should not be overlooked.Morphological variants of this common cancer,including DAC and intraductal carcinoma of the prostate(IDC-P),are associated with poor overall survival and progression-free survival outcomes.Tumours often present with a greater Gleason grade,tumour stage,degree of extraprostatic extension,and lymph node involvement[3,4].The paucity of data on response to different treatment modalities in DAC is explained by the variant’s aggressive nature and low incidence,where recruiting sufficient sample sizes is difficult in order to form accurate conclusions. | Hiten RH.Patel Reena Patel | 2021 | Asian Journal of Urology2021，8，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员